logo-loader

Motif Bio completes rolling submission of NDA for new antibiotic Iclaprim

Published: 03:32 18 Jun 2018 EDT

Graham Lumsden, chief executive of Motif Bio Plc (LON:MTFB), tells Proactive's Andrew Scott they've completed a rolling submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for their new antibiotic Iclaprim.

Lumsden says upon acceptance of the filing of the NDA by the FDA, Iclaprim will receive priority review - a review period of six months instead of the standard ten months.

ARway.ai announces multiple new SaaS developer contracts in both the United...

ARway.ai (CSE:ARWY, OTCQB:ARWYF) Chief Executive Officer Evan Gappelberg joined Steve Darling from Proactive to announce multiple new SaaS developer sign-ups for its augmented reality experience platform, focusing on AR indoor navigation. These partnerships represent significant milestones in...

33 minutes ago